In a closely watched move, a U.K. parliamentary committee is pressuring a pair of key U.K. government agencies and Vertex Pharmaceuticals (VRTX) to settle a long-running dispute over access to a pricey cystic fibrosis drug.
To wit, the Health and Social Care Committee has formally requested documents from the drug maker, the National Health Service in England, and the National Institute for Health and Care Excellence, which is an official cost-effectiveness watchdog, for paperwork that details bitter negotiations over the Orkambi medication. NICE had determined the drug was not worth what Vertex sought to charge.
About the Author Reprints
